add-on maintenance treatment of adult and pediatric patients aged 6 years and older with severe asthma and with an eosinophilic phenotype. NUCALA is not indicated for the relief of acute bronchospasm or status asthmaticus. add-on maintenance treatment of chronic rhinosinusitis with nasal polyps (CRSwN...
INTRODUCTION: Asthma, a prevalent chronic inflammatory disease of the airways, affects an estimated 22 million adult Americans. Severe asthma affects approximately 5% to 10% of patients with asthma; exacerbations requiring hospitalization and ongoing treatment account for a majority of morbidity and ...
Benralizumab is the third anti-IL-5 antibody to be approved for treatment of severe eosinophilic asthma; mepolizumab (Nucala) and reslizumab (Cinqair), which target IL-5 itself, were approved earlier.1,2 Full Text Read More About Pulmonary Medicine Asthma Clinical Pharmacy and Pharmaco...
NUCALA is a prescription medicine for the treatment of people 12 years of age and older with hypereosinophilic syndrome (HES). When you have HES, your eosinophil [ee-uh-sin-uh-fil] levels are elevated. Elevated levels of eosinophils can lead to inflammation throughout your body. This inflamma...
Define eosinophilic. eosinophilic synonyms, eosinophilic pronunciation, eosinophilic translation, English dictionary definition of eosinophilic. adj. 1. Easily stained by eosin or other acid dyes. Used of a cell or cell structure. 2. Of or relating to eo
The Pulmonary-Allergy Drugs Advisory Committee of the US Food and Drug Administration (FDA) has unanimously recommended mepolizumab (Nucala, GlaxoSmithKline) for add-on maintenance treatment in patients aged 18 years or older with severe eosinophilic asthma. ...
The cost of an add-on biological treatment cannot be completely justified when it is not fully effective. This can happen when our therapeutic choices are not perfectly appropriate, with the consequence that a given biologic does not provide an adequate asthma control and further increases health...
These anti-IL-5 drugs have not yet been used clinically for asthma treatment in China. Consequently, this study aims to elucidate the overall safety profile of anti-IL-5 treatments, highlight similarities and differ- ences in their safety profiles, and identify potential novel safety signals to...
Benralizumab is the third anti-IL-5 antibody to be approved for treatment of severe eosinophilic asthma; mepolizumab (Nucala) and reslizumab (Cinqair), which target IL-5 itself, were approved earlier.1,2 Full Text Read More About Pulmonary Medicine Asthma Clinical Pharmacy and Pharmaco...
single technology appraisal (STA) process, the National Institute for Health and Care Excellence (NICE) invited the company (GlaxoSmithKline) that manufactures mepolizumab (Nucala) to submit evidence on the clinical and cost effectiveness of mepolizumab for the treatment of severe eosinophilic asthma. Th...